Christine Harter, MD
Internal Medicine · Glendale, AZNPI 1639133903
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,095 of the $126,942 with a category attached, or 81.2%. AbbVie accounts for 79.7% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2021 at $35,437 and has fallen 99.4% since, to $216 in 2025. Among internal medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 462 payments — averaging $274.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$101K
- Lilly USA, LLC$15K
- Biohaven Pharmaceuticals, Inc.$6K
- Lundbeck LLC$2K
- Amgen$557
- Upsher-smith Laboratories LLC$391
- plus $2K from 23 others
What the payments were for
- Consulting fees$8,3637%
- Speaking & faculty fees$103,09581%
- Travel & lodging$7,2726%
- Food & beverage$7,8316%
- Education$3820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 257 | $101,198 |
| Lilly USA, LLC | 41 | $15,028 |
| Biohaven Pharmaceuticals, Inc. | 9 | $5,906 |
| Lundbeck LLC | 6 | $1,861 |
| Amgen | 21 | $557 |
| Upsher-smith Laboratories LLC | 19 | $391 |
| Supernus Pharmaceuticals, Inc. | 36 | $298 |
| Novo Nordisk | 3 | $234 |
| Teva Pharmaceuticals USA, Inc. | 12 | $192 |
| Impel Pharmaceuticals Inc. | 4 | $176 |
| Amneal Pharmaceuticals LLC | 9 | $168 |
| AstraZeneca | 4 | $158 |
| Pfizer | 3 | $121 |
| Eisai Inc. | 4 | $88 |
| Assertio Therapeutics, Inc. | 5 | $80 |
| Promius Pharma LLC | 4 | $71 |
| Abbott | 2 | $63 |
| Bausch Health US, LLC | 4 | $63 |
| Zyla Life Sciences, Inc. | 4 | $59 |
| Almatica Pharma LLC | 4 | $55 |
| Tactile Systems Technology Inc | 2 | $30 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Edwards Lifesciences | 1 | $25 |
| Medtronic | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Merck | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$126,942 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $37,847 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $19,474 |
| QuliptaAtogepant | 15 | $18,309 |
| Emgality PenGalcanezumab-Gnlm | 26 | $17,465 |
| UbrelvyUbrogepant | 14 | $14,525 |
| Gabapentin | 139 | $3,949 |
| Sumatriptan Succinate | 102 | $3,721 |
| Varenicline Tartrate | 12 | $2,707 |
| SynthroidLevothyroxine Sodium | 24 | $2,279 |
| Rosuvastatin Calcium | 150 | $2,073 |
| Levothyroxine Sodium | 268 | $2,001 |
| Estradiol (Twice Weekly)Estradiol | 16 | $1,996 |
| Omeprazole | 132 | $1,921 |
| Atorvastatin Calcium | 272 | $1,851 |
| Metoprolol Succinate | 95 | $1,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $234 | $37,84728 claims |
| AbbVieQulipta, Ubrelvy, Synthroid | $101,198 | $35,11353 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $168 | $2,001268 claims |
| Upsher-smith Laboratories LLCTopiramate | $391 | $66252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Glendale
- George AvilesGlendale$18K
- Michael CastroGlendale$16K
- Bindu RajanGlendale$16K
- Frank LovecchioPhoenix$911K
- Nasser HajaigPhoenix$687K
- Rajesh JanardhananTucson$685K
- Mona SelejTucson$440K
- Kelly KrohnPhoenix$262K
- Jacque SokolovScottsdale$235K
- Paul StanderPhoenix$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.